Brinzolamide/timolol fixed combination for open-angle glaucoma and ocular hypertension

Abstract

The brinzolamide/timolol fixed combination contains brinzolamide 1% and timolol maleate 0.5% in ophthalmic suspension produced for twice-daily application to reduce elevated intraocular pressure in open-angle glaucoma and ocular hypertension. This fixed combination was recently approved by the European Medicines Agency, in December 2008. The brimzolamide/timolol fixed combination provides an approximately 30–33% intraocular pressure reduction from the untreated baseline of 25–27 mmHg, thus is more potent than any of its ingredients alone and is similarly effective but better tolerated than the dorzolamide/timolol fixed combination, which consists of molecules from the same drug classes. The fixed combination of brinzolamide and timolol can be used as a separate therapy, but due to the additivity of its ingredients to drugs belonging to other classes, it may also be administered in combination with other intraocular pressure-lowering molecules, most importantly topical prostaglandin analogues.

Keywords::

• brinzolamide/timolol fixed combination
• ocular hypertension
• open-angle glaucoma
• ophthalmic suspension

Financial & competing interests disclosure

Gábor Holló is a consultant of and received honoraria from Alcon, Allergan, MSD, Pfizer and Santen. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.